Trial · NCT02808871
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 29
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Developed Any Element of the Composite Endpoint | 52 weeks | Number of participants who developed any element of the composite endpoint of decline in percent predicted FVC of 10% or greater or death. |
| Secondary | Number of Participants With FVC Decline From Baseline of 10% or Greater | 52 weeks | Number of participants with decline from baseline in percent predicted FVC of 10% or greater during the study period. |
| Secondary | Number of Participants With Progressive Disease | 52 weeks | Number of participants with progressive disease as defined by OMERACT: FVC% relative decline of \>=10% or FVC% change in \>=5\< 10% and \>=15% diffusing capacity (DLCO) |
| Secondary | Change in Absolute Value FVC Over the 52 Week Study Period | 52 weeks | Change from baseline to end of study in absolute value of FVC over the 52 week study period |
| Secondary | Change in % Predicted FVC From Baseline to End of Study Over the 52 Week Study Period | 52 weeks | Change from baseline to end of study of percent predicted FVC over the 52 week study period |
| Secondary | Time to Composite of Decline in FVC or Death | 52 weeks | Time to decline of 10% or greater in percent predicted FVC or death while on study |
| Secondary | Change in PRO of Dyspnea | 52 weeks | Change from Baseline to end of study in dyspnea, as measured by the Dyspnea 12 questionnaire - Total scores range from 0 to 36, with higher scores corresponding to greater severity. |
| Secondary | All-cause Mortality | 52 weeks | Number of participants experiencing mortality due to all causes |
| Secondary | All Cause Hospitalization | 52 weeks | Number of participants requiring hospitalization for any cause |
| Secondary | Hospitalization for Respiratory Cause | 52 weeks | Number of participants requiring hospitalization for respiratory cause |
| Secondary | Acute Exacerbations Requiring Hospitalization | 52 weeks | Number of participants experiencing acute exacerbation requiring hospitalization |
| Secondary | Treatment-emergent Adverse Events (AEs) | 52 weeks | Number of participants with treatment-emergent adverse events (AEs) |
| Secondary | Treatment-emergent Serious Adverse Events (SAEs) | 52 weeks | Number of participants with treatment-emergent serious adverse events (SAEs) in the as treated population |
| Secondary | Treatment-emergent/Treatment-related AEs | 52 weeks | Number of participants with treatment-emergent/treatment-related AEs |
| Secondary | Treatment-emergent/Treatment-related SAEs | 52 weeks | Number of participants with treatment-emergent/treatment-related SAEs |
| Secondary | AEs Leading to Early Discontinuation of Study Treatment | 52 weeks | Number of participants with AEs leading to early discontinuation of study treatment |
| Secondary | Treatment-emergent Death or Transplant | 52 weeks | Number of participants who experienced treatment-emergent death or transplant |
| Secondary | Treatment-emergent RA-ILD-related Mortality | 52 weeks | Number of participants who experienced treatment-emergent RA-ILD-related mortality |
| Other | Disease Activity Score (DAS) | 52 weeks | Change from Baseline to end of study in Disease Activity Score (DAS) |
| Other | RAPID3 Score | 52 weeks | Change from baseline to end of study in Routine Assessment of Patient Index Data 3 (RAPID3) score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02808871/registered